Shasqi to Showcase Innovations in Cancer Treatment
Shasqi, Inc. is set to make waves at upcoming international conferences focused on advanced cancer treatments. Among these events, the 15th World ADC conference in San Diego and the Society for the Immunotherapy of Cancer (SITC) Annual Meeting will be key platforms for the biotech company. Shasqi's approach uses in-vivo click chemistry, aiming to enhance the effectiveness of antibody-drug conjugates (ADCs) and radioisotopes.
Key Presentations at the World ADC Conference
During the World ADC event taking place from November 4-7, Shasqi will have several presentations that highlight their recent research. CEO José M. Mejía Oneto and VP of Research Travis Biechele will each present significant findings related to Shasqi's proprietary techniques. These sessions will address the challenges and solutions regarding target-independent toxicities, a common hurdle in the field of ADCs.
Understanding ADC Toxicity
Travis Biechele will be discussing strategies on November 5, focusing on the factors driving toxicity related to ADC treatments. His presentation, titled Understanding the drivers of target independent toxicities associated with ADCs and solutions to overcome them, aims to shed light on mitigating these adverse effects, leading to better patient outcomes.
Innovative Click Chemistry Solutions
On November 6, José M. Mejía Oneto will present his findings on using click chemistry as a potential remedy for ADC-related toxicities. His session, Click chemistry enabled pre-targeting as a solution to target-independent ADC toxicities, proposes innovative solutions for enhancing the application of ADCs.
Poster Sessions Featuring Cutting-Edge Research
Shasqi will also conduct poster sessions to further illustrate their groundbreaking work. These sessions will be critical in providing deeper insights into the effectiveness of Shasqi's CAPAC technology. Posters will cover various topics including the preferential drug exposure in tumors versus normal tissues, showcasing the potential of Shasqi's novel approaches.
Advancements in Cancer Immunotherapy
At the SITC Annual Meeting on November 9, Shasqi will present findings from a Phase 1/2a clinical trial relating to a Doxorubicin-based click chemistry therapeutic. This revolutionary approach aims to activate robust immune responses in patients with advanced sarcoma.
About Shasqi and Its Mission
Shasqi is at the forefront of developing next-generation cancer therapies. Their Click Activated Protodrugs Against Cancer (CAPAC) technology utilizes in-vivo click chemistry for enhanced targeting of treatment. This innovative strategy involves combining a clickable binder with a clickable payload to deliver more precise treatment, targeting cancer cells while sparing healthy tissues.
Investing in Collaborative Opportunities
During these conferences, Shasqi aims to engage with potential partners and collaborators. Establishing relationships with industry leaders and researchers is crucial for advancing their groundbreaking work in cancer treatment technology.
Frequently Asked Questions
What is Shasqi's primary focus at the conferences?
Shasqi aims to showcase their innovative technology and present findings that could enhance the effectiveness of ADCs and immunotherapy treatments.
Who will be presenting on behalf of Shasqi?
CEO José M. Mejía Oneto and VP of Research Travis Biechele will be presenting sessions at both conferences.
What technology will Shasqi be demonstrating?
They will present their Click Activated Protodrugs Against Cancer (CAPAC) technology and its implications for cancer treatments.
When is the World ADC conference?
The World ADC conference will take place from November 4-7.
What are the potential benefits of Shasqi's technology?
Shasqi's technology may lead to safer, more effective cancer therapies by targeting drugs directly to tumor cells, minimizing impact on healthy tissues.
